Se proyecta que el mercado global de inteligencia artificial en genómica alcance los USD 14,61 mil millones para 2029 desde USD 8,34 mil millones en 2022, con una CAGR del 6,1% entre 2023 y 2029.
La genómica es una rama de la ciencia que estudia los genes y sus funciones, así como la estructura, evolución y mapeo de los genomas en organismos vivos. La prueba genética se utiliza para aprender sobre la susceptibilidad a las enfermedades, la respuesta al tratamiento y la biología humana en general. El estudio de la genómica incluye estudios estructurales y funcionales, secuenciación de ADN y bioinformática para secuenciar y recombinar ADN. La aplicación de la inteligencia artificial (IA) en la genómica se centra en la creación de sistemas informáticos que puedan realizar tareas como el mapeo del genoma. La estructura, la evolución y la función del material genético se pueden estudiar más rápidamente con IA que con la interacción humana. Aunque los algoritmos de IA están diseñados para simular la inteligencia humana, también se utilizan en la genómica clínica para realizar análisis genómicos como la anotación del genoma, la identificación de variantes, la correspondencia entre fenotipo y genotipo y la anotación del genoma.
Además, los métodos de IA pueden ayudar a predecir con precisión la estructura de las proteínas o los datos del ADN con una mínima manipulación de las características. La medicina genómica tiene un papel crucial que desempeñar en la medicina personalizada. En este campo, la IA puede ayudar en la producción de medicamentos.
| ATRIBUTO | DETALLES |
| Periodo de estudio | 2022-2029 |
| Año base | 2022 |
| Año estimado | 2023 |
| Año pronosticado | 2023-2029 |
| Periodo histórico | 2018-2022 |
| Unidad | Valor (miles de millones de USD) |
| Segmentación | Por oferta, por tecnología, por funcionalidad, por región. |
| Al ofrecer |
|
| Por tecnología |
|
| Por funcionalidad |
|
| Por región |
|
La necesidad de mantener bajo control los costos y los plazos de desarrollo y descubrimiento de medicamentos está impulsando el mercado de la inteligencia artificial en la genómica. Se espera que el mercado global de la inteligencia artificial en la genómica crezca durante el período proyectado a medida que aumenta la demanda de controlar los costos y el tiempo de descubrimiento durante el desarrollo de nuevos medicamentos. El desarrollo de medicamentos es un proceso que requiere mucho tiempo, es complicado y costoso y requiere la aplicación de varias tecnologías en la búsqueda de nuevos medicamentos. En el descubrimiento y desarrollo de medicamentos, se utilizan ampliamente las técnicas in vivo e in vitro, que son costosas y requieren mucho tiempo. La inteligencia artificial está desempeñando un papel cada vez más importante en el descubrimiento de fármacos, con el potencial de ahorrar una cantidad significativa de tiempo y dinero. Como resultado, durante el período de pronóstico, se espera que el mercado crezca. El mercado está creciendo como resultado del aumento de las inversiones públicas y privadas en IA en genómica. El crecimiento de este mercado está siendo impulsado por la implementación de tecnologías de IA en la medicina de precisión.
Sin embargo, durante el período de pronóstico, se espera que la falta de una fuerza laboral competente en IA y las reglas regulatorias inciertas para el software médico limiten el crecimiento del mercado de inteligencia artificial en genómica. Además, en los últimos años, varios países han realizado importantes inversiones en investigación genómica. Este es un mercado con mucho margen de expansión. Estos gastos han beneficiado sustancialmente el desarrollo de nuevas tecnologías. El Departamento de Biotecnología, por ejemplo, lanzó el Proyecto Genoma de la India (GIP) (DBT). El propósito de este estudio es recolectar 10,000 muestras genéticas de nativos americanos.
The artificial intelligence in genomics market size had crossed USD 8.34 Billion in 2022 and will observe a CAGR of more than 6.1% up to 2029 driven by the burgeoning need to reduce the cost and time of drug development.
The upcoming trend in artificial intelligence in genomics market is focus on developing human-aware AI systems is an opportunity for market growth.
The global artificial intelligence in genomics market registered a CAGR of 6.1% from 2023 to 2029. The technology segment was the highest revenue contributor to the market.
Key players profiled in the report include IBM, Microsoft, NVIDIA Corporation, Deep Genomics, BenevolentAI, Fabric Genomics Inc., Verge Genomics, Freenome Holdings, Inc., MolecularMatch Inc., and Cambridge Cancer Genomics.
North America is the largest regional market with 46% of share Due to the increased acceptance of AI in genome sequencing and rising awareness among regional pharma and biotech organisations, the AI in genomics market in North America is expected to rise.
The artificial intelligence in genomics market is divided into software, services based on offering. AI can take the form of software or tools that can resemble human intelligence in some situations and even outperform it in others. As the complexity of genetic data grows, researchers are turning to artificial intelligence and machine learning to uncover important correlations.
The market is divided into machine learning, computer vision based on technology. Pharmaceutical corporations, contract research organisations, and biotechnology companies all used machine learning for drug genomics applications, which dominated the market. This is due to machine learning's ability to extract insights from enormous data sets, hence speeding up genomic research.
The market is divided into genome sequencing, gene editing, gene mapping based on functionality. Traditional operations and medications are anticipated to be replaced as gene therapy advances. Healthcare providers will be able to treat an illness by putting a gene into their patients' cells. The discovery of gene editing is both delicate and strong.
[caption id="attachment_12641" align="aligncenter" width="680"]
The major players operating in the global artificial intelligence in genomics industry include IBM, Microsoft, NVIDIA Corporation, Deep Genomics, BenevolentAI, Fabric Genomics Inc., Verge Genomics, Freenome Holdings, Inc., MolecularMatch Inc., and Cambridge Cancer Genomics. The presence of established industry players and is characterized by mergers and acquisitions, joint ventures, capacity expansions, substantial distribution, and branding decisions to improve market share and regional presence. Also, they are involved in continuous R&D activities to develop new products as well as are focused on expanding the product portfolio. This is expected to intensify competition and pose a potential threat to the new players entering the market.
21 March, 2022 IBM and Genomics England Forge New Partnership to Transform Patient CareGenomics, the study of how your genes interact with the external world, is transforming how medical science works. England is leading the world in using this information in the healthcare system, enabling clinicians to bring these insights to determine the treatment for a particular patient – this is precision medicine. Understanding genomes can provide evidence to help diagnose disease more quickly and specifically, particularly in cancer and rare diseases. This understanding of disease is important to researchers working to develop new diagnostic tests and treatments – small changes in a genome can show how to target treatments to help more patients in future.
In February 2020, IBM Watson Health signed partnership with Broad Institute of MIT and Harvard (US). An extended partnership will allow the Broad Institute to analyze and explore genomics data to understand intrinsic susceptibility. In October 2020, NVIDIA announced a partnership with global healthcare company GSK and its AI group. GSK’s new hub in London is expected to support its UK based team and scientists from NVIDIA to enhance drug and vaccine discovery using NVIDIA platforms.Geographically, the artificial intelligence in genomics market is segmented into North America, South America, Europe, APAC and MEA.
North America is expected to hold the largest share of the global artificial intelligence in genomics. Due to the increased acceptance of AI in genome sequencing and rising awareness among regional pharma and biotech organisations, the AI in genomics market in North America is expected to rise. In North America, AI deep learning algorithms have also saved countless lives by lowering the time it takes to diagnose diseases patients’ treatment recovery cycle. The implementation of personal genome sequencing testing, particularly for reproductive health, is being driven by growing awareness among European patients. Artificial Intelligence (AI) is widely used in diagnostics and contributes to more accessible, economical, and high-quality healthcare, resulting in increased accuracy.
[caption id="attachment_12642" align="aligncenter" width="680"]
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.